Table 2.
Risk of cardiovascular disease and and major adverse cardiovascular events in patients with AD
| Risk of CVD and MACE in study populations | CVD | MACE | ||||
|---|---|---|---|---|---|---|
| AD cohort | Control cohort | OR (95% CI) | AD cohort | Control cohort | OR (95% CI) | |
| Incident, overall population, n | 130,427 | 392,406 | 1.38 (1.34, 1.41) | 130,427 | 392,406 | 1.40 (1.34, 1.45) |
| % with event | 8.4% | 6.3% | 2.6% | 1.9% | ||
| Patients with metabolic disorders, n | 79,199 | 191,699 | 1.09 (1.07, 1.12) | 89,657 | 214,137 | 1.14 (1.09, 1.18) |
| % with event | 12.1% | 11.2% | 3.7% | 3.3% | ||
| Patients without metabolic disorders, n | 51,228 | 200,707 | 1.25 (1.13, 1.39) | 40,770 | 178,269 | 1.22 (1.01, 1.47) |
| % with event | 1.2% | 0.9% | 0.3% | 0.3% | ||
| Long-term (≥ 3 years) follow-up population | ||||||
| Overall population, n | 29,900 | 108,058 | 1.76 (1.69, 1.82) | 29,900 | 108,508 | 1.68 (1.58, 1.78) |
| % with event | 17.0% | 10.4% | 5.2% | 3.1% | ||
| Patients with metabolic disorders, n | 22,195 | 61,421 | 1.33 (1.28, 1.38) | 24,573 | 67,320 | 1.30 (1.23, 1.39) |
| % with event | 20.5% | 16.3% | 6.2% | 4.8% | ||
| Patients without metabolic disorders, n | 7705 | 46,637 | 1.41 (1.15, 1.71) | 5327 | 41,188 | 1.46 (1.01, 2.10) |
| % with event | 2.2% | 1.4% | 0.7% | 0.5% | ||
AD atopic dermatitis, CI confidence interval, CVD cardiovascular disease, MACE major adverse cardiovascular events, OR odds ratio